Background: Discrete choice experiment (DCE) as a tool that can measure medical
stakeholders' preferences especially patients recently has been increasingly applied in …

Background Targeted pharmacotherapy has been increasingly applied in cancer treatment
due to its breakthroughs. However, the unmet needs of cancer patients are still significant …

Purpose: No published head-to-head randomized trials have compared the safety and
efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration …

Background Recently approved second‐generation androgen receptor inhibitors (SGARIs)
for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but …

Aims: To describe the incidence and identify prognostic factors of central nervous system
(CNS) adverse events (AEs) and any AEs (CNS, skin rash, or fracture) and evaluate the …

Introduction Given the relatively short life expectancy of patients with hepatocellular
carcinoma (HCC), quality of life (QOL) plays a significant role in treatment selection. This …

Background The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors
offered dyslipidemia patients an alternative to statins for lipid‐lowering treatment …

Introduction Three novel androgen receptor inhibitors are approved in the USA for the
treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide …

Background Patient preference studies can inform decision-making across all stages of the
medical product life cycle (MPLC). The treatment landscape for advanced prostate cancer …

Background Recent approvals of second-generation androgen receptor inhibitors (SGARIs)
have changed the treatment landscape for non-metastatic castration-resistant prostate …